Niagen Bioscience, Inc. (NAGE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.17+1.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NAGE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 129.1 | 129.4 | 99.6 | 83.6 | 72.1 | 67.4 | 59.3 | 46.3 | 31.6 | 21.2 | 21.7 | 17.9 | 15.3 | 10.2 | 11.6 | 8.1 |
| Total Revenues | 129.1 | 129.4 | 99.6 | 83.6 | 72.1 | 67.4 | 59.3 | 46.3 | 31.6 | — | — | — | — | — | — | — |
| Cost of Revenues | 46.2 | 46.2 | 38.0 | 32.8 | 29.3 | 26.0 | 24.0 | 20.5 | 15.5 | 10.7 | 11.3 | 10.4 | 10.0 | 7.0 | 9.3 | 5.6 |
| Gross Profit | 82.9 | 83.2 | 61.6 | 50.8 | 42.8 | 41.5 | 35.3 | 25.8 | 16.1 | 10.5 | 10.4 | 7.5 | 5.3 | 3.1 | 2.3 | 2.5 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 6.5 | 6.3 | 6.0 | 5.0 | 4.8 | 3.8 | 3.4 | 4.4 | 5.5 | 4.0 | 2.5 | 0.9 | 0.5 | 0.1 | 0.1 | — |
| Operating Income | 10.6 | 16.3 | 7.7 | (5.6) | (18.6) | (27.1) | (19.9) | (31.3) | (33.2) | (16.4) | (2.9) | (2.1) | (5.2) | (4.4) | (11.6) | (7.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | 0.1 | 0.1 | 0.8 | 0.1 | 0.2 | 0.3 | 0.6 | 0.2 | 0.0 | 0.0 | (0.0) |
| Interest & Investment Income | — | 2.1 | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | 0.3 | 0.6 | 0.2 | 0.0 | 0.0 | (0.0) |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | (0.1) | (0.8) | (0.1) | (0.2) | (0.6) | (0.6) | (0.2) | (0.0) | (0.0) | (0.0) |
| EBT, Incl. Unusual Items | 17.0 | 18.2 | 8.9 | (4.9) | — | — | — | — | — | (16.5) | (3.6) | (2.6) | — | — | — | — |
| Income Tax Expense | 1.0 | 0.8 | 0.3 | 0.0 | — | — | — | — | — | 0.0 | 0.0 | (0.0) | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 16.0 | 17.4 | 8.6 | (4.9) | (16.5) | (27.1) | (19.9) | (32.1) | (33.3) | (11.4) | (2.9) | (2.8) | (5.4) | (4.4) | (11.7) | (7.9) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.20 | 0.22 | 0.11 | (0.07) | (0.24) | (0.40) | (0.33) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 0.19 | 0.20 | 0.11 | (0.07) | (0.24) | (0.40) | (0.33) | — | — | — | — | — | — | — | — | (0.12) |
| Revenue per Share | 1.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 79.3 | 79.2 | 75.9 | 75.0 | 69.7 | 67.2 | 61.1 | — | — | — | 37.3 | 35.9 | 35.5 | 100.0 | 90.3 | — |
| Diluted Weighted Avg Shares | 82.5 | 85.4 | 78.1 | 75.0 | 69.7 | 67.2 | 61.1 | — | — | — | — | — | — | 100.6 | 96.0 | 76.0 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | (32.6) | (15.9) | (2.6) | (1.8) | — | — | — | — |
| EBIT | 10.6 | 16.3 | 7.7 | (5.6) | (18.6) | (27.1) | (19.9) | (31.3) | (33.2) | (16.4) | (2.9) | (2.1) | (5.2) | (4.4) | (11.6) | (7.9) |
| Effective Tax Rate | 6.1% | — | — | 0.0% | — | — | — | — | — | 0.0% | 0.0% | 0.2% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.